Jazz Pharmaceuticals plc — Director's Dealing 2022

Aug 17, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2022-08-15

Reporting Person: Carr Patricia (SVP, Chief Accounting Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-08-15	Ordinary Shares	S	142	$156.86	Disposed	5934	Direct
2022-08-15	Ordinary Shares	M	2000	$113.1	Acquired	7934	Direct
2022-08-15	Ordinary Shares	S	2000	$160.29	Disposed	5934	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-08-15	Non-Qualified Stock Option (right to buy)	$113.1	M	2000	Disposed	2030-02-26	Ordinary Shares (2000)	Direct

Footnotes

F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: These options are granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, February 27, 2020, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter.